|Articles|February 4, 2013
CRF Health's TrialMax ePRO Instrument Achieves Validation Standard
Advertisement
CRF Health has now deployed spirometer integration together with the ACQ and AQLQ in several global studies on TrialMax Touch™ and TrialMax Slate™ with four major Pharmaceutical companies. Including these programs, CRF Health’s clinical reach and breadth using Professor Juniper’s instruments spans nearly 40 countries, 3000 patients, and more than 40 languages. In addition to these, CRF Health has deployed a further 15 studies using Professor Juniper’s ACQ and AQLQ instruments (but without spirometer integration).
TrialMax® solutions are available for 5 platforms including Windows, Windows Mobile, Android, Palm OS and Web, thus allowing clients to select the right platform, technology and hardware to support their clinical trials. The combination of CRF Health’s clinical expertise and innovation of ePRO collection methods, combined with patient engagement and retention tools, offer new ways to improve study execution and subject compliance.
In a recent study discussion, Professor Elizabeth Juniper commented, “I feel it is important, when evaluating a new technology device to determine whether it will give valid data, to keep in mind that validity is more likely to be achieved if the screen shots are similar to the original format especially when translating languages with longer text.”
TrialMax® solutions are available for 5 platforms including Windows, Windows Mobile, Android, Palm OS and Web, thus allowing clients to select the right platform, technology and hardware to support their clinical trials. The combination of CRF Health’s clinical expertise and innovation of ePRO collection methods, combined with patient engagement and retention tools, offer new ways to improve study execution and subject compliance.
In a recent study discussion, Professor Elizabeth Juniper commented, “I feel it is important, when evaluating a new technology device to determine whether it will give valid data, to keep in mind that validity is more likely to be achieved if the screen shots are similar to the original format especially when translating languages with longer text.”
“Professor Elizabeth Juniper’s diligence and research integrity is a model for the industry. We are excited to have had the opportunity to collaborate and to jointly achieve this industry milestone. It is through our engagement with researchers and instrument authors such as Professor Elizabeth Juniper that we continually enhance our regulatory rigor, technology competence and patient research integrity through clinical expertise and innovation ,” commented Rachael Wyllie , CEO of CRF Health.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- How Recent Policy Changes Could Impact Clinical Research
September 10th 2025
- Ensuring Digital Trial Platforms Work for Underserved Communities
September 10th 2025
- eClinical Technology: Misconceptions, Challenges, and Opportunities
September 9th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Investigational PD-L1 x VEGF-A Bispecific Antibody Demonstrates Strong Overall Response Rate in Phase II Small Cell Lung Cancer Trial
2
Phase III EMPOWER-Lung 3 Trial Confirms Five-Year Survival Benefit With Libtayo Plus Chemotherapy in NSCLC
3
Investigational OX40-Targetting T-Cell Therapy Shows Durable Efficacy Treating Atopic Dermatitis in Phase III Trial
4
eClinical Technology: Misconceptions, Challenges, and Opportunities
5